No Data
Wuxi Bio [02269] is now trading at HKD 10.76, a decrease of 5.12%.
As of 09:32, Wuxi Bio [02269] reported a price of HKD 10.76, a decrease of HKD 0.58 or 5.12% from the previous closing price of HKD 11.34. The transaction amount was HKD 82.5358 million. The highest price today was HKD 11.3, and the lowest price was HKD 10.76. Based on the closing price of yesterday, the 10-day average price is HKD 13.48, and the 50-day average price is HKD 14.00. The current P/E ratio is 13.18 times, and the 14-day strength index is 19.51.
Express News | Shares of WuXi Biologics Down More Than 3%
Express News | Hong Kong Shares of WuXi AppTec Fall More Than 4% as US Bill to Restrict Business With Wuxi Passes House
Guosen Securities maintains a 'outperform' rating on Wuxi Bio (02269) and indicates that its production capacity layout is gradually improving.
Jingu Caixun | Guosen Securities issued a research report, Wuxi Bio (02269) achieved a revenue of 8.574 billion yuan in the first half of the year (+1.0%, excluding income from new crown projects +7.7%), with a net income attributable to the mother of 1.499 billion yuan (-33.9%), and an adjusted net income of 2.54 billion yuan (-13.0%) under IFRS. The expense structure remained robust, with the sales expense ratio for H1 2024 at 2.6% (+1.4pp), the management expense ratio at 9.0% (+1.0pp), and the financial expense ratio at 0.8% (-0.1pp). The bank pointed out that all technical platforms of the company achieved positive results in the first half of 2024.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
The U.S. House of Representatives passed the Biosecure Act.
On September 9th, the US House of Representatives announced that the Biosecure Act (H.R.8333) was passed with 306 votes in favor and 81 votes against. The act, which is based on national security concerns, restricts business dealings between US federal institutions and foreign biotechnology companies, and specifically names five Chinese companies: wuxi apptec (02359), its sister company wuxi bio (02269), bgi genomics, bgi genomics affiliate company bgi tech (688114), and
AnaiAnai : Bad news.![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)